Table 3 Enriched pathways involving the predicted target genes
Pathway name | p value |
|---|---|
Pathways in cancer | 5.60E-16 |
MAPK signaling pathway | 1.70E-14 |
Endocytosis | 6.90E-14 |
Neurotrophin signaling pathway | 1.50E-13 |
Wnt signaling pathway | 6.50E-13 |
Focal adhesion | 7.60E-11 |
Axon guidance | 1.10E-10 |
ErbB signaling pathway | 7.10E-09 |
Glioma | 5.80E-08 |
Basal cell carcinoma | 6.20E-08 |
Long-term potentiation | 6.30E-08 |
TGF-beta signaling pathway | 9.10E-08 |
Regulation of actin cytoskeleton | 1.10E-07 |
mTOR signaling pathway | 3.70E-07 |
Adherens junction | 1.30E-06 |
Chemokine signaling pathway | 1.10E-05 |
Long-term depression | 1.90E-05 |
T cell receptor signaling pathway | 3.00E-05 |
Gap junction | 5.60E-05 |
Fc gamma R-mediated phagocytosis | 1.60E-04 |
B cell receptor signaling pathway | 4.60E-04 |
GnRH signaling pathway | 5.40E-04 |
Fc epsilon RI signaling pathway | 7.60E-04 |
Phosphatidylinositol signaling system | 1.50E-03 |
VEGF signaling pathway | 1.50E-03 |
Vascular smooth muscle contraction | 2.20E-03 |
SNARE interactions in vesicular transport | 2.40E-03 |
ECM-receptor interaction | 2.40E-03 |